pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 2 · small molecule · Achondroplasia
Voxzogo (vosoritide) is a subcutaneous injection approved for the treatment of achondroplasia, the most common form of dwarfism. The drug is a C-type natriuretic peptide (CNP) analog that works by stimulating bone growth through a specific cellular pathway. Developed by BioMarin Pharmaceutical Australia Pty Ltd, vosori
Internal code 111-205
Voxzogo (vosoritide) is a subcutaneous injection approved for the treatment of achondroplasia, the most common form of dwarfism. The drug is a C-type natriuretic peptide (CNP) analog that works by stimulating bone growth through a specific cellular pathway. Developed by BioMarin Pharmaceutical Australia Pty Ltd, vosoritide represents a disease-modifying approach to achondroplasia, addressing a significant unmet medical need in a rare genetic disorder affecting skeletal development.
Voxzogo has achieved regulatory approval across major markets: approved in Australia (May 2023), the European Union (November 2025), and the United States. The program is currently in Phase 2 development, with an ongoing open-label extension study evaluating long-term safety, tolerability, and efficacy in children with achondroplasia. The extension study is tracking outcomes in the pediatric population, the primary target demographic for this indication.
BioMarin's strategy focuses on establishing vosoritide as a foundational therapy for achondroplasia management, with regulatory approvals already secured in key markets. The Phase 2 extension study provides critical long-term safety and efficacy data to support continued clinical use and potential label expansions. The drug is formulated in two strengths (0.56 mg and 1.2 mg powder for injection) to accommodate dosing flexibility across different patient populations.
Achondroplasia is a rare genetic disorder with significant clinical and quality-of-life implications for affected individuals and families. The condition results in disproportionate short stature, skeletal deformities, and potential complications including spinal stenosis and neurological issues. Prior to vosoritide's approval, no disease-modifying pharmacological treatments were available; management was limited to supportive care and surgical intervention for complications.
Voxzogo addresses a critical unmet medical need by offering the first pharmacological option to stimulate longitudinal bone growth in achondroplasia patients. The drug's mechanism—activation of the natriuretic peptide receptor pathway—represents a novel biological approach distinct from growth hormone therapy, which has limited efficacy in achondroplasia. This positions vosoritide as a potentially transformative option for pediatric patients, where early intervention during growth years may yield substantial clinical benefits.
The commercial significance is substantial given the orphan disease designation, regulatory incentives, and the global patient population estimated in the thousands. Approvals across Australia, the EU, and the US establish a multi-market commercial footprint. The Phase 2 extension study generates real-world long-term safety and efficacy data critical for physician confidence, payer coverage decisions, and potential label expansions to additional patient populations or age groups.
Competitive positioning is strengthened by vosoritide's unique mechanism and first-mover advantage in the CNP analog space for achondroplasia. While other musculo-skeletal therapies exist (bisphosphonates, denosumab, growth hormone), none specifically target the pathophysiology of achondroplasia with the same mechanism of action, making vosoritide a distinct therapeutic option.
Drug Class: C-type natriuretic peptide (CNP) analog; musculo-skeletal system therapeutic (ATC M05).
Modality: Small molecule.
Route of Administration: Subcutaneous injection.
Mechanism of Action: Not yet disclosed in available documentation; however, vosoritide is a CNP analog that stimulates bone growth through activation of natriuretic peptide receptor pathways, promoting endochondral ossification and longitudinal bone growth.
Target: Not yet disclosed; mechanism implies natriuretic peptide receptor signaling pathways in cartilage and bone.
Formulations: Available in two strengths—0.56 mg and 1.2 mg powder with solvent for solution for injection.
First Approval: United States (NDA 214938); Australia (May 2023, PBS codes 13270K, 13274P, 13275Q); European Union (November 17, 2025, EMEA/H/C/005475).
Patent Status: Not yet disclosed.
Related Therapies: Growth hormone therapy (limited efficacy in achondroplasia); bisphosphonates and denosumab (for bone density management in other conditions); recombinant human growth hormone (approved comparator in some markets).
Also known as: ACH, achondroplastic dwarfism
Prevalence: Prevalence at birth: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Achondroplasia is the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
ClinicalTrials.gov lists 46 registered studies for Achondroplasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (16), PHASE3 (4), PHASE2/PHASE3 (3), PHASE1 (2), PHASE1/PHASE2 (1), PHASE4 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007037), Orphanet — achondroplasia, NCT00001536, NCT01435629, NCT01516229, NCT01541306, NCT01590446, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 Open-Label Extension Study Ongoing
Long-term safety, tolerability, and efficacy evaluation of vosoritide (BMN 111) in children with achondroplasia; study status active.
Australian Regulatory Approval
Voxzogo approved in Australia; listed on ARTG with PBS codes 13270K, 13274P, 13275Q.
European Union Regulatory Approval
Voxzogo approved by EMA; EMEA product number EMEA/H/C/005475; MAH BioMarin International Limited.
The competitive landscape for achondroplasia treatment includes several approved musculo-skeletal therapies, though most address bone density or growth rather than achondroplasia-specific pathophysiology. Approved competitors listed include bisphosphonates (ibandronic acid, alendronic acid formulations), denosumab products (Corora by Amgen; Vysribli), and other bone-active agents (Aclasta, Evenity by Amgen, Osseor, Inductos). Additionally, recombinant human growth hormone is approved as a comparator in some markets.
Crysvita (burosumab, KYOWA KIRIN AUSTRALIA) represents a competing rare disease therapy but targets hypophosphatemic rickets rather than achondroplasia. Voxzogo's competitive advantage lies in its CNP analog mechanism, which directly addresses achondroplasia's underlying pathophysiology by stimulating endochondral bone growth—a mechanism distinct from growth hormone, bisphosphonates, or other approved agents. This differentiation positions vosoritide as the first disease-modifying pharmacological therapy specifically designed for achondroplasia, rather than an off-label adaptation of therapies developed for other conditions.
The competitive moat is reinforced by regulatory exclusivity (orphan drug designation), first-mover advantage in the CNP analog space for achondroplasia, and approvals across major markets (US, EU, Australia). No competing CNP analogs for achondroplasia are noted in the facts, suggesting limited direct competition in this specific mechanism class.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Recombinant human growth hormone | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Approved |
| INFIGRATINIB | — | Fibroblast growth factor receptor inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Voxzogo approved; NDA 214938 filed by BIOMARIN PHARM. Approval date not yet disclosed in available facts.
European Union: Voxzogo approved November 17, 2025; EMA product number EMEA/H/C/005475; Marketing Authorization Holder (MAH) BioMarin International Limited. Full EPAR available at https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo.
Australia: Voxzogo approved May 1, 2023; listed on ARTG (Australian Register of Therapeutic Goods). PBS codes: 13270K, 13274P, 13275Q. Sponsor: BioMarin Pharmaceutical Australia Pty Ltd. Evidence available at https://www.tga.gov.au/resources/artg?keywords=vosoritide.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Orphan Drug Designation: Status not yet disclosed in available documentation; however, achondroplasia's rare disease status typically qualifies for orphan drug incentives in major markets.
Voxzogo (vosoritide) is approved for the treatment of achondroplasia, the most common form of dwarfism, a rare genetic disorder affecting skeletal development and longitudinal bone growth.
Yes, Voxzogo is approved in the United States (NDA 214938), the European Union (November 17, 2025), and Australia (May 1, 2023). Regulatory status in Japan and China is not yet disclosed.
Voxzogo is a C-type natriuretic peptide (CNP) analog that stimulates bone growth by activating natriuretic peptide receptor pathways, promoting endochondral ossification and longitudinal bone growth in achondroplasia patients.
Voxzogo is developed and manufactured by BioMarin Pharmaceutical Australia Pty Ltd (Australian sponsor) and BioMarin International Limited (European Marketing Authorization Holder).
Voxzogo is administered as a subcutaneous injection, available in two strengths: 0.56 mg and 1.2 mg powder with solvent for solution.
A Phase 2 open-label extension study (NCT 2023-508754-26-00) is currently ongoing to evaluate long-term safety, tolerability, and efficacy in children with achondroplasia. Pivotal trial details are not yet disclosed.
Voxzogo is in Phase 2 development, with an active open-label extension study evaluating long-term outcomes. The drug has already achieved regulatory approval in major markets.
Achondroplasia is a rare genetic disorder causing disproportionate short stature, skeletal deformities, and potential complications including spinal stenosis and neurological issues. It is the most common form of dwarfism.
Prior to Voxzogo, no disease-modifying pharmacological treatments were available for achondroplasia. Management was limited to supportive care and surgical intervention. Other musculo-skeletal therapies (bisphosphonates, growth hormone) exist but do not specifically target achondroplasia's pathophysiology.
Vosoritide is a C-type natriuretic peptide analog that activates natriuretic peptide receptor signaling pathways to stimulate endochondral bone growth, representing a novel biological approach distinct from growth hormone therapy.
Voxzogo is listed on the Australian Register of Therapeutic Goods with PBS codes 13270K, 13274P, and 13275Q.
The EMA product number for Voxzogo is EMEA/H/C/005475, with approval granted November 17, 2025.
Regulatory status in Japan (PMDA) and China (NMPA) is not yet disclosed in available documentation.
Voxzogo is classified as a musculo-skeletal system therapeutic (ATC code M05) and is a small-molecule C-type natriuretic peptide analog.
Voxzogo is designed for children with achondroplasia, with the Phase 2 extension study specifically evaluating outcomes in the pediatric population during critical growth years.
Orphan drug designation status is not yet disclosed in available facts; however, achondroplasia's rare disease status typically qualifies for orphan drug incentives in major regulatory markets.
Voxzogo is available in two strengths: 0.56 mg powder and solvent for solution for injection, and 1.2 mg powder and solvent for solution for injection, allowing dosing flexibility across patient populations.
111-205 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: BioMarin has successfully established vosoritide as the first disease-modifying pharmacological therapy for achondroplasia across three major regulatory regions (US, EU, Australia). The Phase 2 extension study represents a critical post-approval data generation strategy, providing long-term safety and efficacy evidence to support physician adoption, payer coverage, and potential label expansions to younger age groups or additional patient populations.
Competitive Implications: Voxzogo's CNP analog mechanism and first-mover advantage create a defensible competitive position. The absence of competing CNP analogs in the facts suggests limited near-term competition in this specific mechanism class. However, future competitive threats may emerge from alternative growth-stimulating approaches or improved formulations of existing therapies. BioMarin's multi-market approvals and ongoing clinical data generation establish barriers to entry for potential competitors.
Future Catalysts: Completion and publication of the Phase 2 extension study data will be critical for demonstrating long-term safety and efficacy, supporting expanded clinical use and potential label extensions. Additional catalysts may include: (1) regulatory approvals in Japan and China, expanding the addressable market; (2) data from pediatric subgroup analyses; (3) potential label expansions to additional age groups or patient populations; (4) real-world evidence studies supporting long-term outcomes and quality-of-life benefits.
Expected Milestones: Specific milestone dates are not yet disclosed. However, anticipated events include completion of the Phase 2 extension study, publication of long-term safety and efficacy data, and potential regulatory submissions in additional markets (Japan, China). Peak sales projections are not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.